Company profile ELOX
After 39 days of this quarter the interest is at 100.0. Based on that we can calculate that during remaining 52 days it will total up to 233.0. Eloxx Pharmaceuticals expected interest is significantly higher compared to previous quarter (+140.2%) and same quarter last year (+210.7%).
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 57 | 167 193.0% QoQ | 146 -12.6% QoQ | 125 -14.4% QoQ |
| 2020 | 52 -8.8% YoY -58.4% QoQ | 31 -81.4% YoY -40.4% QoQ | 35 -76.0% YoY 12.9% QoQ | 116 -7.2% YoY 231.4% QoQ |
| 2021 | 57 9.6% YoY -50.9% QoQ | 158 409.7% YoY 177.2% QoQ | 114 225.7% YoY -27.8% QoQ | 83 -28.4% YoY -27.2% QoQ |
| 2022 | 114 100.0% YoY 37.3% QoQ | 134 -15.2% YoY 17.5% QoQ | 47 -58.8% YoY -64.9% QoQ | 74 -10.8% YoY 57.4% QoQ |
| 2023 | 75 -34.2% YoY 1.4% QoQ | 135 0.7% YoY 80.0% QoQ | 77 63.8% YoY -43.0% QoQ | 97 31.1% YoY 26.0% QoQ |
| 2024 | 100 33.3% YoY 3.1% QoQ | - | - | - |
The average 5 years interest of Eloxx Pharmaceuticals was 7.64 per week. The last year interest of Eloxx Pharmaceuticals compared to the last 5 years has changed by 10.99%. This is something to be checked. The last year interest is comparable to 5 years ago. It has changed only by -10.92%.
There is not enough data for ELX-02 clinical trial to provide analysis
There is not enough data for ELX-02 clinical trial to provide correlation calculation
There is not enough data for ELX-02 clinical trial to provide analysis
After 39 days of this quarter the interest is at 166.0. Based on that we can calculate that during remaining 52 days it will total up to 387.0. Cystic fibrosis treatment expected interest is significantly lower compared to previous quarter (-47.1%) and same quarter last year (-58.4%).
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 565 | 572 1.2% QoQ | 488 -14.7% QoQ | 754 54.5% QoQ |
| 2020 | 842 49.0% YoY 11.7% QoQ | 608 6.3% YoY -27.8% QoQ | 394 -19.3% YoY -35.2% QoQ | 496 -34.2% YoY 25.9% QoQ |
| 2021 | 518 -38.5% YoY 4.4% QoQ | 506 -16.8% YoY -2.3% QoQ | 353 -10.4% YoY -30.2% QoQ | 498 0.4% YoY 41.1% QoQ |
| 2022 | 704 35.9% YoY 41.4% QoQ | 717 41.7% YoY 1.8% QoQ | 437 23.8% YoY -39.1% QoQ | 689 38.4% YoY 57.7% QoQ |
| 2023 | 930 32.1% YoY 35.0% QoQ | 710 -1.0% YoY -23.7% QoQ | 513 17.4% YoY -27.7% QoQ | 731 6.1% YoY 42.5% QoQ |
| 2024 | 166 -82.2% YoY -77.3% QoQ | - | - | - |
The average 5 years interest of Cystic fibrosis treatment was 46.71 per week. The last year interest of Cystic fibrosis treatment compared to the last 5 years has changed by 10.0%. The interest for Cystic fibrosis treatment is seasonal. The last year interest is comparable to 5 years ago. It has changed only by -0.35%.
There is not enough data for Nephropathic cystinosis treatment to provide analysis
There is not enough data for Nephropathic cystinosis treatment to provide correlation calculation
There is not enough data for Nephropathic cystinosis treatment to provide analysis
After 39 days of this quarter the interest is at 103.0. Based on that we can calculate that during remaining 52 days it will total up to 240.0. Alport syndrome treatment expected interest is significantly higher compared to previous quarter (+11900.0%) and same quarter last year (+1614.3%).
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 0 | 13 inf% QoQ | 14 7.7% QoQ | 7 -50.0% QoQ |
| 2020 | 5 inf% YoY -28.6% QoQ | 24 84.6% YoY 380.0% QoQ | 21 50.0% YoY -12.5% QoQ | 6 -14.3% YoY -71.4% QoQ |
| 2021 | 8 60.0% YoY 33.3% QoQ | 14 -41.7% YoY 75.0% QoQ | 28 33.3% YoY 100.0% QoQ | 0 -100.0% YoY -100.0% QoQ |
| 2022 | 4 -50.0% YoY inf% QoQ | 7 -50.0% YoY 75.0% QoQ | 17 -39.3% YoY 142.9% QoQ | 14 inf% YoY -17.6% QoQ |
| 2023 | 14 250.0% YoY 0.0% QoQ | 2 -71.4% YoY -85.7% QoQ | 7 -58.8% YoY 250.0% QoQ | 2 -85.7% YoY -71.4% QoQ |
| 2024 | 103 635.7% YoY 5050.0% QoQ | - | - | - |
The average 5 years interest of Alport syndrome treatment was 1.19 per week. The last year interest of Alport syndrome treatment compared to the last 5 years has changed by 95.8%. This is something to be checked. The last year interest is quite higher compared to 5 years ago. It has increased by 247.76%.
There is not enough data for Recessive dystrophic epidermolysis bullosa treatment to provide analysis
There is not enough data for Recessive dystrophic epidermolysis bullosa treatment to provide correlation calculation
There is not enough data for Recessive dystrophic epidermolysis bullosa treatment to provide analysis
There is not enough data for Junctional epidermolysis bullosa treatment to provide analysis
There is not enough data for Junctional epidermolysis bullosa treatment to provide correlation calculation
There is not enough data for Junctional epidermolysis bullosa treatment to provide analysis
After 39 days of this quarter the interest is at 0.0. Based on that we can calculate that during remaining 52 days it will total up to 0.0. Familial adenomatous polyposis treatment expected interest is significantly lower compared to previous quarter (-100.0%) and same quarter last year (-100.0%).
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 80 | 68 -15.0% QoQ | 47 -30.9% QoQ | 34 -27.7% QoQ |
| 2020 | 116 45.0% YoY 241.2% QoQ | 69 1.5% YoY -40.5% QoQ | 0 -100.0% YoY -100.0% QoQ | 176 417.6% YoY inf% QoQ |
| 2021 | 31 -73.3% YoY -82.4% QoQ | 61 -11.6% YoY 96.8% QoQ | 36 inf% YoY -41.0% QoQ | 29 -83.5% YoY -19.4% QoQ |
| 2022 | 0 -100.0% YoY -100.0% QoQ | 71 16.4% YoY inf% QoQ | 28 -22.2% YoY -60.6% QoQ | 159 448.3% YoY 467.9% QoQ |
| 2023 | 35 inf% YoY -78.0% QoQ | 31 -56.3% YoY -11.4% QoQ | 25 -10.7% YoY -19.4% QoQ | 34 -78.6% YoY 36.0% QoQ |
| 2024 | 0 -100.0% YoY -100.0% QoQ | - | - | - |
The average 5 years interest of Familial adenomatous polyposis treatment was 4.33 per week. The last year interest of Familial adenomatous polyposis treatment compared to the last 5 years has changed by -53.81%. This is something to be checked. The last year interest is quite lower compared to 5 years ago. It has decreased by -58.59%.
There is not enough data for Eloxx Pharmaceuticals stock price to provide analysis
There is not enough data for Eloxx Pharmaceuticals stock price to provide correlation calculation
There is not enough data for Eloxx Pharmaceuticals stock price to provide analysis
There is not enough data for Eloxx Pharmaceuticals -stock -company to provide analysis
There is not enough data for Eloxx Pharmaceuticals -stock -company to provide correlation calculation
There is not enough data for Eloxx Pharmaceuticals -stock -company to provide analysis